Article Versions Notes

Yamasaki S, Hashiguchi M, Yoshida-Sakai N, Jojima H, Osaki K, Okamura T, Imamura Y. Efficacy of Anti-CD38 Monoclonal Antibodies for Relapsed or Refractory Multiple Myeloma in Stem Cell Transplant-Ineligible Patients Aged over 65 Years: A Propensity Score-Matched Study. Hematology Reports. 2024; 16(4):714-723. https://doi.org/10.3390/hematolrep16040068

Yamasaki, Satoshi, Michitoshi Hashiguchi, Nao Yoshida-Sakai, Hiroto Jojima, Koichi Osaki, Takashi Okamura, and Yutaka Imamura. 2024. "Efficacy of Anti-CD38 Monoclonal Antibodies for Relapsed or Refractory Multiple Myeloma in Stem Cell Transplant-Ineligible Patients Aged over 65 Years: A Propensity Score-Matched Study" Hematology Reports 16, no. 4: 714-723. https://doi.org/10.3390/hematolrep16040068

Yamasaki, S., Hashiguchi, M., Yoshida-Sakai, N., Jojima, H., Osaki, K., Okamura, T., & Imamura, Y. (2024). Efficacy of Anti-CD38 Monoclonal Antibodies for Relapsed or Refractory Multiple Myeloma in Stem Cell Transplant-Ineligible Patients Aged over 65 Years: A Propensity Score-Matched Study. Hematology Reports, 16(4), 714-723. https://doi.org/10.3390/hematolrep16040068